A Multicentre Phase 3 Trial Comparing Elotuzumab-Cyclophosphamide-Thalidomide-Dexamethasone (E-CTD) with Cyclophosphamide-Thalidomide-Dexamethasone (CTD) for the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM)
Latest Information Update: 18 Apr 2022
At a glance
- Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 16 May 2018 Status changed from not yet recruiting to recruiting.
- 05 Aug 2016 New trial record